



BSW Formulary Updates and Recent Decisions – December 2023

New additions to BSWformulary and Change in Traffic Light Status

- [Trifarotene cream \(Aklief®\)](#) – Additional treatment option in therapeutic class of topical retinoids, added with **GREEN** TLS. Useful option in people ≥12years for truncal acne due to pump dispenser format and specific evidence base. Now included in [BSW Acne Guidance](#)
- [Daridorexant 25mg and 50mg tablets \(Quviviq®\)](#) added with **GREEN** TLS for treating long-term insomnia in line with [NICE TA922](#). We are currently working on guidance for primary care.
- [Rimegepant 75mg oral lyophilisates \(Vydura®\)](#) added with **GREEN** TLS for treating migraine in line with [NICE TA919](#). We are currently working on guidance for primary care. Please note, prophylactic use of Rimegepant for preventing migraine remains a RED TLS indication.

New and Updated Shared Care Agreements and Prescribing Guidance

- **UPDATE** – [BSW Primary Care Guidance for Inclisiran](#) – BSW ICB position statement updated.
- **UPDATE** – [Topical testosterone for adult women on HRT](#) – Testavan and Testim removed and changes to initiation process for specialists and GPs.
- **UPDATE** – [BSW Acne Guidance](#) – Aklief® added as treatment option.
- **UPDATE** – [BSW Creatinine Clearance Electronic Tool for Primary Care](#) – updated version and calculator included on SystemOne.
- **UPDATE** – [BSW Anticoagulation in NVAf](#) – update to flow chart 3 with apixaban now first choice and further information added.
- **UPDATE** – [BSW Dry Eye Guidance](#) – link to [MHRA DSI/2023/11](#) included for information as some affected brands of carbomer eye gel are in our guidance
- **NEW** – [SGLT-2i Comparison Chart produced by Diabetes Specialist Nurse Forum UK](#) link added.

Minor amendments to BSW formulary

- New strengths of azathioprine (75mg and 100mg) have been marketed and are very expensive. A [non-formulary entry has been added to formulary](#). No local specialists have expressed an interest in using these strengths.
- [Pentoxifylline 400mg MR tablets](#) have been aligned for BSW with a RED TLS for the off-label treatment of osteoradionecrosis (usually given in combination with oral Vitamin E). If practices are currently prescribing pentoxifylline on FP10 for existing patients, please seek advice from bswicb.formulary@nhs.net
- Newly launched [omeprazole liquid 5mg/5ml](#) (Rosemont) added as non-formulary. For cost-effective preferred formulations, refer to formulary entries and [BSW PPI for GORD in paediatric patients](#). (Note this document is under review).
- [Oral liothyronine entry](#) amended as liothyronine 20 microgram tablets are now more cost-effective than 20 microgram capsules. The SCA for this drug is currently under review.
- Updated [oral glucose entry](#) to reflect products used in acute Trust setting.



What the BSW CCG formulary team are currently working on

- Updating the treatment of VTE guidance
- Tirzepatide – This will be available for prescribing in line with [NICE TA924](#) once manufacturers have provided clarification on UK availability and formulation. We are working on further guidance on Traffic Light Status and the place of tirzepatide in the BSW Type 2 diabetes pathway. Further information to follow when we have this clarification.
- Reviewing the national NHSE [Shared Care Protocols](#) for implementation locally. A SCA for Valproate for women of childbearing potential has been prioritised in view of the national safety workstream.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net